Stelis Biopharma, an associate company of Strides, has provided the following update about the transaction with Syngene to transfer Stelis' Unit 3 multi-modal facility in Bengaluru.
Syngene concludes acquisition of biologics manufacturing facility from Stelis
Akston Biosciences Ends Vaccine Partnership with Stelis, Continues to Advance COVID Universal Booster EUA
Strides Pharma Science on Wednesday said its arm Stelis Biopharma has received an establishment inspection report (EIR) from the US health regulator specific to drug-device combination products to be commercialised at its flagship facility in Bengaluru. This follows the abbreviated quality system inspection technique drug pre-approval on-site inspection specifically conducted by the US Food and Drug Administration (USFDA) for the drug-device combination products that are to be manufactured and c ..
Unable to sell its huge stock of Covid vaccine Sputnik Light amid the Russia-Ukraine conflict, the Bengaluru-based Stelis Biopharma has written to Prime Minister Narendra Modi requesting for procurement of the jabs for inoculating citizens here or supplying to other countries under the Vaccine Maitri programme.
Stelis Biopharma, a vertically integrated biopharma and vaccines company and the biotech arm of Strides Pharma Science Limited, has appointed Mark W. Womack as the new CEO. He is also the managing director designate and will be inducted to the board later subject to necessary statutory clearances and processes.
Stelis Biopharma has closed its Series B and Series C fundraise for US $195 million, which will be used to progress the company’s growth initiatives and help scale its business.
The Russian Direct Investment Fund (RDIF) and Stelis Biopharma have today announced a partnership which aims to produce and supply a minimum of 200 million doses of the Russian Sputnik V vaccine globally.
Strides Pharma Science, which had sold its injectable unit Agila Specialties to Mylan in 2013, is all set to re-enter injectables business again.